Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03932201 · ClinicalTrials.gov registry record
Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A
A clinical trial of Hemophilia A, sponsored by Bayer.
- Active
- Registry status
- 371
- Enrollment target
- 20
- Study locations
NCT03932201 is a study of Hemophilia A that is active but no longer recruiting, run by Bayer. The registered enrollment target is 371 participants, above the 83-participant average among 42 other Hemophilia A trials with a reported enrollment target (347% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT03932201, a study of Hemophilia A, is active but no longer recruiting, sponsored by Bayer.
- ACTIVE NOT RECRUITING
- Registry status
- 371 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of the HEM-POWR study is to understand better how Damoctocog alfa pegol (Jivi) is used to treat people with Hemophilia A in day-to-day life, how well the treatment is tolerated and how satisfied patients and physicians are with the treatment.
Conditions Studied
Interventions
- DRUG Damoctocog alfa pegol (Jivi, Bay94-9027)
Study Locations (20)
Other
- Many locations - Multiple Locations
- Many locations - Multiple Locations
- Many locations - Multiple Locations
- Many locations - Multiple Locations
- Many locations - Multiple Locations
- Many locations - Multiple Locations
- Many locations - Multiple Locations
- Many locations - Multiple Locations
- Many locations - Multiple Locations
- Many locations - Multiple Locations
California
- University California Davis - Davis
- Orthopaedic Hospital DBA Orthopaedic Institute for Children - Los Angeles
- The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders - Orange
Alabama
- South Alabama Medical Science Foundation - Mobile
Arizona
- Banner MD Anderson Cancer Center - Phoenix
Colorado
- University of Colorado Hemophilia and Thrombosis Center - Aurora
District of Columbia
- Georgetown University - Washington D.C.
Louisiana
- Tulane University - New Orleans
Minnesota
- Regents of University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 371 participants |
| Start Date | 2019-10-21 |
| Est. Completion | 2027-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03932201
The ClinicalTrials.gov registry entry for NCT03932201 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 371 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 83-participant average among 42 other Hemophilia A trials with a reported enrollment target (347% higher). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which Damoctocog alfa pegol (Jivi, Bay94-9027) is the first listed.
NCT03932201 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT03932201 about?
NCT03932201 is a clinical study titled "Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A". The aim of the HEM-POWR study is to understand better how Damoctocog alfa pegol (Jivi) is used to treat people with Hemophilia A in day-to-day life, how well the treatment is tolerated and how satisfied patients and physicians are with the treatment.
What is the current status of trial NCT03932201?
This trial is currently active not recruiting. The enrollment target is 371 participants. The study started on 2019-10-21. Estimated completion is 2027-03-31.
What conditions does trial NCT03932201 study?
This clinical trial studies the following conditions: Hemophilia A.
What interventions are being tested in trial NCT03932201?
The interventions under investigation include: Damoctocog alfa pegol (Jivi, Bay94-9027) (DRUG).
Who is sponsoring clinical trial NCT03932201?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03932201 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RECRUITING · Phase 3
-
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
RECRUITING · Phase 1
-
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
RECRUITING · Phase 4
-
Hemophilia A Research Program
RECRUITING
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.